A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorRegeneron Pharmaceuticals

About this trial

This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels).

The aim of the study is to see how safe and effective alirocumab is when given weekly to adult participants who have hypercholesterolemia.

The study is looking at several other research questions, including:

* What side effects may happen from taking the study drug once a week * How much study drug is in the blood at different times

Eligibility criteria

Qualifiers

None

Disqualifiers

Participant plans to initiate or change dose of lipid-lowering therapy

Use of any PCSK9 inhibitors

Trial design

Treatments tested in this trial

  • Alirocumab

Treatment groups

420 Participants
are divided into 4 treatment groups

Sponsors and collaborators